Candriam S.C.A. Acquires 61,973 Shares of Dyne Therapeutics, Inc. $DYN

Key Points

• Candriam S.C.A. increased its holdings in Dyne Therapeutics, Inc. by 15.4%, acquiring an additional 61,973 shares, bringing its total to approximately 463,368 shares valued at $4.8 million.
• Several institutional investors, including Caitong International Asset Management and E Fund Management, have also significantly increased their stakes in Dyne Therapeutics, contributing to institutional ownership of 96.68%.
• Analysts currently have a consensus rating of "Buy" for Dyne Therapeutics, with an average target price of $33.80, despite recent adjustments in target prices from various firms.

Candriam S.C.A. raised its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 15.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 463,368 shares of the company's stock after purchasing an additional 61,973 shares during the period. Candriam S.C.A. owned approximately 0.41% of Dyne Therapeutics worth $4,847,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of DYN. Caitong International Asset Management Co. Ltd boosted its holdings in Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after purchasing an additional 2,446 shares during the period. GF Fund Management CO. LTD. bought a new stake in Dyne Therapeutics in the 4th quarter valued at about $50,000. E Fund Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after purchasing an additional 1,923 shares during the period. Fox Run Management L.L.C. bought a new stake in Dyne Therapeutics in the 1st quarter valued at about $179,000. Finally, Arizona State Retirement System boosted its holdings in Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after purchasing an additional 1,481 shares during the period. Institutional investors own 96.68% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Evercore ISI reissued an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Raymond James Financial restated an "outperform" rating and issued a $31.00 target price (down from $37.00) on shares of Dyne Therapeutics in a research report on Tuesday, July 29th. Stifel Nicolaus dropped their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Royal Bank Of Canada dropped their target price on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, July 29th. Finally, Chardan Capital dropped their target price on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of "Buy" and an average target price of $33.80.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox acquired 100,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer directly owned 242,179 shares in the company, valued at $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.14% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Price Performance

DYN stock opened at $12.58 on Friday. The company has a 50 day simple moving average of $10.23 and a 200 day simple moving average of $11.23. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -3.26 and a beta of 1.08. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $46.81. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02. Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.